株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌の世界市場予測

Global Oncology Market Forecast 2023

発行 NAVADHI Market Research Pvt Ltd 商品コード 847108
出版日 ページ情報 英文 283 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
癌の世界市場予測 Global Oncology Market Forecast 2023
出版日: 2019年05月17日 ページ情報: 英文 283 Pages
概要

当レポートでは、世界の癌治療薬市場について、市場構造、市場動向、市場成長の促進要因・抑制要因を含めて詳細に分析しており、癌市場関連のリスク、主な業界団体、競合情勢、および主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 イントロダクション:医薬品産業

第3章 世界の癌市場のニーズ

  • 世界人口の増加 & 高齢化
  • 貧困 & 中産階級世帯の所得水準の上昇

第4章 世界の癌市場の予測

  • 治療領域別の予測:世界の医薬品市場

第5章 世界の癌市場における促進要因・抑制要因

第6章 世界の癌市場に関連するリスク

  • 特許失効・知的財産保護を喪失するリスク
  • 新製品の商業的成功リスク
  • R&Dへの取り組みが失敗するリスク
  • 薬価管理のリスク
  • 新たな法規制の遵守に失敗するリスク
  • 複雑な製造工程における品質管理のリスク
  • サイバー攻撃・データ漏えいのリスク
  • 為替レート・金利変動のリスク
  • 不安定な世界政治・経済状態のリスク

第7章 世界の医薬品市場関連の業界団体

  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • nternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Association of the British Pharmaceutical Industry (ABPI)
  • 日本製薬工業協会 (JPMA)
  • Indian Drug Manufacturers' Association (IDMA)

第8章 世界の癌市場における主要企業のプロファイル

  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • AstraZeneca PLC
  • Roche Holding AG
  • Merck & Co., Inc.
  • Astellas Pharma Inc
  • AbbVie Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squib Company

第9章 世界の癌市場における競合情勢

  • 上位10社の競合情勢:癌関連の収益
  • 上位10社の競合情勢:総収益
  • 上位10社の競合情勢:世界の医薬品収益
  • 上位10社の競合情勢:米国の医薬品収益
  • 上位10社の競合情勢:R&D支出額
  • 上位10社の競合情勢:EPS (1株当たり利益)
  • 上位10社の競合情勢:EBITDA
  • 上位10社の競合情勢:総収益予測
  • 上位10社の競合情勢:上位3製品の収益

第10章 世界の癌市場分析

  • ポーターのファイブフォース分析
  • SWOT分析

第11章 世界の癌市場における現在・将来の動向

目次
Product Code: NAV0519001

Global oncology market is expected to grow in near future as aging and growing population, rising income levels, and emerging medical conditions and emergence of new diseases help increase the demand for oncology treatment.

“Global oncology market is expected to be worth USD 202.54 billion by 2023.”

As per NAVADHI Market Research, global oncology pharmaceutical market will we worth USD 202.54 billion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

Oncology had the largest revenue share in Global pharmaceuticals market in FY 2018, and it is expected to retain in it's leadership position even in 2023.

This growth in oncology market is fueled by the growing and ageing population in key markets. As per World Population Prospects by United Nations, the worldwide population is likely to cross 9.3 billion by 2050 and around 21% of this population is expected to be aged 60 and above. Apart from ageing and rising population the improvements in purchasing power and access to quality healthcare and pharmaceuticals to poor and middle-class families worldwide also is driving the growth of global oncology industry. Another aspect which is leading this growth is rising focus of pharmaceuticals companies to tap the rare and specialty diseases market. Innovations in advanced biologics, nucleic acid therapeutics, cell therapies and bioelectronics & implantables has attracted investments in the industry which is fueling this growth.

On the other hand, adoption of cost control policies along with tightening of rules by governments in key markets are expected to impact the growth prospect of the global oncology industry. Oncology companies are forced to reduce their research and development (R&D) spending due to slowdown of growth in last few years which is also expected to hamper growth of the global oncology market as new drugs revenue form large part of pharma firm's revenue due to exclusivity of the drug. Apart from this, generics pharma market is facing decreasing return on investment due to price erosion in key markets which is forcing many firms to look for other avenues and markets to sustain growth.

On 3rd January 2019, Bristol-Myers Squibb Company which was ranked 4th based on their FY 2018 oncology revenue announced their plan to acquire Celgene Corporation which was ranked 2nd in the world. The acquisition is expected to cost around USD 90 billion to Bristol-Myers Squibb Company. Post-acquisition Bristol-Myers Squibb Company is expected to give tough competition to Roche Holding AG which is currently world's top oncology company by FY 2018 revenue.

Spanning over 283 pages and 201 exhibits, “Global Oncology Market Forecast 2023” report provides in-depth analysis for the global oncology pharmaceuticals market for the year FY2018 to FY2023, including market structure, market trends, market constraints and industry drivers.

This report includes detailed company profiles including their position in Global pharmaceuticals market value chain, financial performance analysis, product wise business strategy, competitive landscape and SWOT analysis for 10 key players in Global oncology market namely: Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc, AstraZeneca PLC, Eli Lilly, AbbVie Inc and Astellas Pharma Inc.

Scope of the “Global Oncology Market Forecast 2023” Report:

  • This report provides detailed information about Global oncology market including future market forecasts till 2023.
  • This report identifies the need for focusing on global oncology market.
  • The report identifies the growth drivers and inhibitors for global oncology market.
  • The report identifies various risks associated with global oncology market.
  • This report has detailed profiles top 10 key players in Global oncology market covering their business strategy, financial performance, future forecasts and SWOT analysis.
  • This report provides competitive landscape among top 10 key companies in Global oncology market.
  • This report provides Porter's Five Forces analysis for Global oncology market.
  • This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Global oncology market.
  • This report provides information about current and future trends for Global oncology market.

COMPANIES COVERED:

  • 1. Roche Holding AG
  • 2. Novartis AG
  • 3. Bristol-Myers Squibb Company
  • 4. Johnson & Johnson
  • 5. Merck & Co., Inc.
  • 6. Pfizer Inc.
  • 7. AstraZeneca PLC
  • 8. Eli Lilly
  • 9. AbbVie Inc.
  • 10. Astellas Pharma Inc

Table of Contents

1. Executive Summary

  • Scope of the Global Oncology Market Forecast 2023 Report
  • Research Methodology

2. Introduction of Pharmaceuticals Industry

  • Key Product Terms Used in Pharmaceuticals Industry
  • Pharmaceuticals
  • Innovative Drugs
  • Orphan Drugs
  • Generic Drugs
  • Commodity Generic Drugs
  • Branded Generic Drugs
  • Biologics
  • Biosimilars
  • Over-the-counter (OTC) Drugs
  • Active Pharmaceutical Ingredients (APIs)
  • Excipients
  • Research and Development (R&D) Phases of Pharmaceuticals Industry
  • Industry-Wise Research and Development (R&D) Investment
  • Phase Wise Research and Development (R&D) Investment in Pharmaceuticals Industry
  • Global Pharmaceuticals Industry Value Chain Analysis

3. Need for Global Oncology Market

  • Rising & Ageing Global Population
  • Increasing Income Levels of Poor & Middle-Class Families

4. Forecast for Global Oncology Market 2023

  • 4.1. Therapy Area-Wise Forecast for Global Pharmaceuticals Market 2018-2023
    • 4.1.1. Forecast for Global Oncology Pharmaceuticals Market 2018-2023

5. Growth Drivers and Inhibitors for Global Oncology Market

6. Risks Associated with Global Oncology Market

  • 6.1. Risk of Patent Expiry and Loss of Intellectual Property Protection
  • 6.2. Risk of Commercial Success of New Products
  • 6.3. Risk of Failed Research and Development Effort
  • 6.4. Risk of Drug Price Controls
  • 6.5. Risk of Failure to Comply with New Laws and Regulations
  • 6.6. Risk of Quality Control During Complex Manufacturing Process
  • 6.7. Risk of Cyber-Attacks and Data Breach
  • 6.8. Risk of Volatile Currency Exchange Rates and Interest Rates
  • 6.9. Risk of Unstable Global Political and Economic Conditions

7. Industry Associations Related to Global Pharmaceuticals Market

  • 7.1. European Federation of Pharmaceutical Industries and Associations(EFPIA)
  • 7.2. International Federation of Pharmaceutical Manufacturers & Associations(IFPMA)
  • 7.3. Pharmaceutical Research and Manufacturers of America(PhRMA)
  • 7.4. Association of the British Pharmaceutical Industry(ABPI)
  • 7.5. Japan Pharmaceutical Manufacturers Association(JPMA)
  • 7.6. Indian Drug Manufacturers' Association(IDMA)

8. Profile of Key Players in Global Oncology Market

  • 8.1. Pfizer Inc.
    • 8.1.1. Company Profile
    • 8.1.2. Pfizer Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.1.3. Pfizer Inc.: Financial Performance
      • 8.1.3.1. Pfizer Inc.: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.1.3.2. Pfizer Inc.: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.1.3.3. Pfizer Inc.: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.1.4. Pfizer Inc.: Business Strategy
      • 8.1.4.1. Product Level Strategy
    • 8.1.5. SWOT Analysis of Pfizer Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.2. Novartis AG
    • 8.2.1. Company Profile
    • 8.2.2. Novartis AG in Global Pharmaceuticals Manufacturing Value Chain
    • 8.2.3. Novartis AG: Financial Performance
      • 8.2.3.1. Novartis AG: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.2.3.2. Novartis AG: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.2.3.3. Novartis AG: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.2.4. Novartis AG: Business Strategy
    • 8.2.5. SWOT Analysis of Novartis AG
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.3. Johnson & Johnson
    • 8.3.1. Company Profile
    • 8.3.2. Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
    • 8.3.3. Johnson & Johnson Financial Performance
      • 8.3.3.1. Johnson & Johnson: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.3.3.2. Johnson & Johnson: Division-Wise Revenue FY 2018(in USD billion)
      • 8.3.3.3. Johnson & Johnson: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.3.3.4. Johnson & Johnson: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.3.4. Johnson & Johnson: Business Strategy
      • 8.3.4.1. Product Level Business Strategy
    • 8.3.5. Johnson & Johnson's Pharmaceutical Division Growth Drivers
    • 8.3.6. SWOT Analysis of Johnson & Johnson
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.4. AstraZeneca PLC
    • 8.4.1. Company Profile
    • 8.4.2. AstraZeneca PLC in Global Pharmaceuticals Manufacturing Value Chain
    • 8.4.3. AstraZeneca PLC: Financial Performance
      • 8.4.3.1. AstraZeneca PLC: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.4.3.2. AstraZeneca PLC: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.4.3.3. AstraZeneca PLC: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.4.4. AstraZeneca PLC: Business Strategy
      • 8.4.4.1. Product Level Strategy
    • 8.4.5. SWOT Analysis of AstraZeneca PLC
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.5. Roche Holding AG
    • 8.5.1. Company Profile
    • 8.5.2. Roche Holding AG in Global Pharmaceuticals Manufacturing Value Chain
    • 8.5.3. Roche Holding AG: Financial Performance
      • 8.5.3.1. Roche Holding AG: Overall Revenue FY 2013-FY 2019(in CHF billion)
      • 8.5.3.2. Roche Holding AG: Geography-Wise Revenue FY 2018(in CHF billion)
      • 8.5.3.3. Roche Holding AG: Division-Wise Revenue FY 2018(in CHF billion)
      • 8.5.3.4. Roche Holding AG: Therapy Area-Wise Pharmaceuticals Revenue FY 2018(in CHF billion)
      • 8.5.3.5. Roche Holding AG: Segment-Wise Diagnostics Revenue FY 2018(in CHF billion)
    • 8.5.4. Roche Holding AG: Business Strategy
      • 8.5.4.1. Product Level Strategy
    • 8.5.5. SWOT Analysis of Roche Holding AG
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 8.5.6. Key Customers of Roche Holding AG
  • 8.6. Merck & Co., Inc.
    • 8.6.1. Company Profile
    • 8.6.2. Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.6.3. Merck & Co., Inc.: Financial Performance
      • 8.6.3.1. Merck & Co., Inc.: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.6.3.2. Merck & Co., Inc.: Division-Wise Revenue FY 2018(in USD billion)
      • 8.6.3.3. Merck & Co., Inc.: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.6.3.4. Merck & Co., Inc.: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.6.4. Merck & Co., Inc.: Business Strategy
      • 8.6.4.1. Product Level Strategy
    • 8.6.5. SWOT Analysis of Merck & Co., Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.7. Astellas Pharma Inc
    • 8.7.1. Company Profile
    • 8.7.2. Astellas Pharma Inc. in Pharmaceuticals Manufacturing Value Chain
    • 8.7.3. Astellas Pharma Inc.: Financial Performance
      • 8.7.3.1. Astellas Pharma Inc: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.4.3.2. Astellas Pharma Inc: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.7.3.3. Astellas Pharma Inc: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.7.4. Astellas Pharma Inc.: Business Strategy
      • 8.7.4.1. Product Level Strategy
    • 8.7.5. SWOT Analysis of Astellas Pharma Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • 8.7.6. Key Customers of Astellas Pharma Inc.
  • 8.8. AbbVie Inc.
    • 8.8.1. Company Profile
    • 8.8.2. AbbVie Inc. in Global Pharmaceuticals Manufacturing Value Chain
    • 8.8.3. AbbVie Inc.: Financial Performance
      • 8.8.3.1. AbbVie Inc.: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.8.3.2. AbbVie Inc.: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.8.3.3. AbbVie Inc.: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.8.4. AbbVie Inc.: Business Strategy
      • 8.8.4.1. Product Level Strategy
    • 8.8.5. SWOT Analysis of AbbVie Inc.
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.9. Eli Lilly and Company
    • 8.9.1. Company Profile
    • 8.9.2. Eli Lilly in Global Pharmaceuticals Manufacturing Value Chain
    • 8.9.3. Eli Lilly: Financial Performance
      • 8.9.3.1. Eli Lilly: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.9.3.2. Eli Lilly: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.9.3.3. Eli Lilly: Division-Wise Revenue FY 2018(in USD billion)
      • 8.9.3.4. Eli Lilly: Geography-Wise Pharmaceuticals Revenue FY 2018(in USD billion)
      • 8.9.3.5. Eli Lilly: Therapy Area-Wise Revenue FY 2018(in USD billion)
    • 8.9.4. Eli Lilly: Business Strategy
      • 8.9.4.1. Product Level Strategy
    • 8.9.5. SWOT Analysis of Eli Lilly and Company
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • 8.10. Bristol-Myers Squib Company
    • 8.10.1. Company Profile
    • 8.10.2. Bristol-Myers Squibb Company in Pharmaceuticals Manufacturing Value Chain
    • 8.10.3. Bristol-Myers Squibb Company: Financial Performance
      • 8.10.3.1. Bristol-Myers Squibb Company: Overall Revenue FY 2013-FY 2019(in USD billion)
      • 8.10.3.2. Bristol-Myers Squibb Company: Geography-Wise Revenue FY 2018(in USD billion)
      • 8.10.3.3. Bristol-Myers Squibb Company: Brand-Wise Pharmaceuticals Revenue FY 2018(in USD billion)
    • 8.10.4. Bristol-Myers Squibb Company: Business Strategy
      • 8.10.4.1. Product Level Strategy
    • 8.10.5. SWOT Analysis of Bristol-Myers Squibb Company
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats

9. Competitive Landscape in Global Oncology Market

  • 9.1. Competitive Landscape Among Top 10 Oncology Companies by Oncology Revenue
  • 9.2. Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue
  • 9.3. Competitive Landscape Among Top 10 Oncology Companies by Global Pharmaceuticals Revenue
  • 9.4. Competitive Landscape Among Top 10 Oncology Companies by United States Revenue
  • 9.5. Competitive Landscape Among Top 10 Oncology Companies by Research and Development(R&D) Expenditure
  • 9.6. Competitive Landscape Among Top 10 Oncology Companies by Earning Per Share(EPS)
  • 9.7. Competitive Landscape Among Top 10 Oncology Companies by Earnings Before Interest, Tax, Depreciation and Amortization(EBITDA)
  • 9.8. Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue Forecast
  • 9.9. Competitive Landscape Among Top 10 Oncology Companies by Top 3 Product Revenues

10. Analysis of Global Oncology Market

  • 10.1. Porter's Five Forces Analysis of Global Oncology Market
  • 10.2. SWOT Analysis of Global Oncology Market
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats

11. Current and Future Trends in Global Oncology Market

  • List of Exhibits
  • Notes
  • Company Information

List of Exhibits

  • Exhibit 2.1: Research and Development Phases of Pharmaceuticals Industry
  • Exhibit 2.2: Industry-Wise Research and Development Investment in Comparison to Net Sales (in %)
  • Exhibit 2.3: Phase-Wise Research and Development Investment in Pharmaceuticals Industry
  • Exhibit 2.4: Global Pharmaceuticals Industry Value Chain Analysis
  • Exhibit 3.1: Country-Wise Population Forecast 2016-2023 (in millions)
  • Exhibit 3.2: Country-Wise Purchasing Power Parity Based Per Capita GDP Forecast 2016-2023 (in USD)
  • Exhibit 4.1: Therapy Area-wise Market Share in Global Pharmaceuticals Market in 2017 (in %)
  • Exhibit 4.2: Forecast for Global Oncology Pharmaceuticals Market 2018-2023 (in USD billion)
  • Exhibit 5.1: Growth Drivers and Inhibitors for Global Oncology Market
  • Exhibit 6.1: Country-Wise Drug Price Control Policies in Global Pharmaceuticals Market
  • Exhibit 7.1: Key Information of EFPIA
  • Exhibit 7.2: Contact details of EFPIA
  • Exhibit 7.3: List of EFPIA Members
  • Exhibit 7.4: Key Information of IFPMA
  • Exhibit 7.5: Contact details of IFPMA
  • Exhibit 7.6: List of IFPMA Members
  • Exhibit 7.7: Key Information of PhRMA
  • Exhibit 7.8: Contact details of PhRMA
  • Exhibit 7.9: List of PhRMA Members
  • Exhibit 7.10: Key information of ABPI
  • Exhibit 7.11: Contact details of ABPI
  • Exhibit 7.12: List of ABPI Members
  • Exhibit 7.13: Key Information of JPMA
  • Exhibit 7.13: Key Information of JPMA
  • Exhibit 7.15: List of JPMA Members
  • Exhibit 7.16: Key information of IDMA
  • Exhibit 7.17: Contact details of IDMA
  • Exhibit 8.1: Key Information of Pfizer Inc.
  • Exhibit 8.2: Contact information of Pfizer Inc.
  • Exhibit 8.3: Pfizer Inc. in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.4: Revenue of Pfizer Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.5: Revenue Growth of Pfizer Inc. FY 2014- FY 2019 (in %)
  • Exhibit 8.6: Geography-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
  • Exhibit 8.7: Therapy Area-Wise Revenue of Pfizer Inc. in FY 2018 (in USD billion)
  • Exhibit 8.8: Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD billion)j
  • Exhibit 8.9: SWOT Analysis of Pfizer Inc.
  • Exhibit 8.10: Key Information of Novartis AG
  • Exhibit 8.11: Contact Information of Novartis AG
  • Exhibit 8.12: Novartis AG in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.13: Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.14: Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)
  • Exhibit 8.15: Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)
  • Exhibit 8.16: Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)
  • Exhibit 8.17: Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)
  • Exhibit 8.18: Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
  • Exhibit 8.19: Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
  • Exhibit 8.20: Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)
  • Exhibit 8.21: 10+ potential blockbuster launches planned by Novartis AG in the next 2 years
  • Exhibit 8.22: SWOT Analysis of Novartis AG
  • Exhibit 8.23: Key Information of Johnson & Johnson
  • Exhibit 8.24: Contact information of Johnson & Johnson
  • Exhibit 8.25: Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.26: Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.27: Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
  • Exhibit 8.28: Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.29: Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.30: Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.31: Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.32: Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.33: Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
  • Exhibit 8.34: Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
  • Exhibit 8.35: SWOT Analysis of Johnson & Johnson
  • Exhibit 8.36: Key Information of AstraZeneca PLC
  • Exhibit 8.37: Contact Information of AstraZeneca PLC
  • Exhibit 8.38: AstraZeneca PLC in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.39: Revenue of AstraZeneca PLC FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.40: Revenue Growth of AstraZeneca PLC FY 2014-FY 2019 (in %)
  • Exhibit 8.41: Geography-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
  • Exhibit 8.42: United States Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.43: United States Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.44: China Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.45: China Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.46: United Kingdom Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.47: United Kingdom Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.48: France Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.49: France Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.50: Germany Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.51: Germany Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.52: Italy Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.53: Italy Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.54: Spain Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.55: Spain Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.56: Sweden Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.57: Sweden Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.58: Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.59: Rest of Europe Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.60: Rest of Europe Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.61: Canada Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.62: Rest of Americas Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.63: Rest of Americas Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.64: Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.65: Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.66: Japan Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.67: Japan Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.68: Rest of Asia, Africa & Australia Revenue of AstraZeneca PLC FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.69: Rest of Asia, Africa & Australia Revenue Growth of AstraZeneca PLC FY 2015-FY 2018 (in %)
  • Exhibit 8.70: Therapy Area-Wise Revenue of AstraZeneca PLC in FY 2018 (in USD billion)
  • Exhibit 8.71: Therapy and Geography Area-Wise Revenue of AstraZeneca PLC FY 2018 (in USD billion)
  • Exhibit 8.72: SWOT Analysis of AstraZeneca PLC
  • Exhibit 8.73: Key Information of Roche Holding AG
  • Exhibit 8.74: Contact Information of Roche Holding AG
  • Exhibit 8.75: Roche Holding AG in Global Pharmaceutical Manufacturing Value Chain
  • Exhibit 8.76: Revenue of Roche Holding AG FY 2013- FY 2019 (in CHF billion)
  • Exhibit 8.77: Revenue Growth of Roche Holding AG FY 2014- FY 2019 (in %)
  • Exhibit 8.78: Geography-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
  • Exhibit 8.79: Division-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
  • Exhibit 8.80: Pharmaceuticals Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
  • Exhibit 8.81: County-Wise Pharmaceuticals Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.82: Diagnostics Division Revenue of Roche Holding AG FY 2013- FY 2018 (in CHF billion)
  • Exhibit 8.83: County-Wise Diagnostics Division Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.84: Therapy Area-Wise Revenue of Roche Holding AG in FY 2018 (in CHF billion)
  • Exhibit 8.85: Therapy Area-Wise Pharmaceuticals Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.86: Segment-Wise Diagnostics Revenue of Roche Holding AG FY 2018 (in CHF billion)
  • Exhibit 8.87: SWOT Analysis of Roche Holding AG
  • Exhibit 8.88: Roche Holding AG Pharmaceuticals Product Pipeline
  • Exhibit 8.89: Key Information of Merck & Co.
  • Exhibit 8.90: Contact Information of Merck & Co.
  • Exhibit 8.91: Merck & Co., Inc. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.92: Revenue of Merck & Co., Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.93: Revenue Growth of Merck & Co., Inc. FY 2014-FY 2019 (in %)
  • Exhibit 8.94: Division-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.95: Pharmaceuticals Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.96: Animal Health Division Revenue of Merck & Co., Inc. FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.97: Geography-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.98: Therapy Area-Wise Revenue of Merck & Co., Inc. in FY 2018 (in USD billion)
  • Exhibit 8.99: Business Division, Therapy Area and Geography Area-Wise Revenue of Merck & Co., Inc. FY 2018 (in USD billion)
  • Exhibit 8.100: SWOT Analysis of Merck & Co., Inc.
  • Exhibit 8.101: Key Information of Astellas Pharma Inc
  • Exhibit 8.102: Contact information of Astellas Pharma Inc
  • Exhibit 8.103: Astellas Pharma Inc in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.104: Revenue of Astellas Pharma Inc FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.105: Revenue Growth of Astellas Pharma Inc FY 2014-FY 2019 (in %)
  • Exhibit 8.106: Geography-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
  • Exhibit 8.107: Japan Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.108: Japan Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
  • Exhibit 8.109: Americas Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.110: Americas Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
  • Exhibit 8.111: EMEA Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.112: EMEA Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
  • Exhibit 8.113: Asia & Oceania Revenue of Astellas Pharma Inc FY 2014-FY 2018 (in USD billion)
  • Exhibit 8.114: Asia & Oceania Revenue Growth of Astellas Pharma Inc FY 2015-FY 2018 (in %)
  • Exhibit 8.115: Therapy Area-Wise Revenue of Astellas Pharma Inc in FY 2018 (in USD billion)
  • Exhibit 8.116: Therapy and Geography Area-Wise Revenue of Astellas Pharma Inc FY 2018 (in USD billion)
  • Exhibit 8.117: SWOT Analysis of Astellas Pharma Inc
  • Exhibit 8.118: Key information of AbbVie Inc.
  • Exhibit 8.119: Contact Information of AbbVie. Inc.
  • Exhibit 8.120: AbbVie. Inc. in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.121: Revenue of AbbVie Inc. FY 2013- FY 2019 (in USD billion)
  • Exhibit 8.122: Revenue Growth of AbbVie Inc. FY 2014-FY 2019 (in %)
  • Exhibit 8.123: Geography-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
  • Exhibit 8.124: Therapy Area-Wise Revenue of AbbVie Inc. in FY 2018 (in USD billion)
  • Exhibit 8.125: Therapy Area and Geography Area-Wise Revenue of AbbVie Inc. FY 2018 (in USD billion)
  • Exhibit 8.126: SWOT Analysis of AbbVie Inc.
  • Exhibit 8.127: Key information of Eli Lilly
  • Exhibit 8.128: Contact Information Eli Lilly
  • Exhibit 8.129: Eli Lilly in Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.130: Revenue of Eli Lilly and Company FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.131: Revenue Growth of Eli Lilly and Company FY 2014-FY 2019 (in %)
  • Exhibit 8.132: Geography-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.133: United States Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.134: United States Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
  • Exhibit 8.135: Rest of World Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.136: Rest of World Revenue Growth of Eli Lilly and Company FY 2014-FY 2018 (in %)
  • Exhibit 8.137: Division-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.138: Pharmaceuticals Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.139: Animal Health Division Revenue of Eli Lilly and Company FY 2013- FY 2018 (in USD billion)
  • Exhibit 8.140: Geography-Wise Pharmaceuticals Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.141: United States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.142: Europe States Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.143: Japan Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.144: Rest of World Pharmaceuticals Revenue of Eli Lilly and Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.145: Therapy Area-Wise Revenue of Eli Lilly and Company in FY 2018 (in USD billion)
  • Exhibit 8.146: Business Division-Wise, Therapy and Geography Area-Wise Revenue of Eli Lilly and Company FY 2018 (in USD million)
  • Exhibit 8.147: SWOT Analysis of Eli Lilly and Company
  • Exhibit 8.148: Key Information of Bristol-Myers Squib Company
  • Exhibit 8.149: Contact Information of Bristol-Myers Squib Company
  • Exhibit 8.150: Bristol-Myers Squib Company in Global Pharmaceuticals Manufacturing Value Chain
  • Exhibit 8.151: Revenue of Bristol-Myers Squibb Company FY 2013-FY 2019 (in USD billion)
  • Exhibit 8.152: Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2019 (in %)
  • Exhibit 8.153: Geography-Wise Revenue of Bristol-Myers Squibb Company in FY 2018 (in USD billion)
  • Exhibit 8.154: United States Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.155: United States Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.156: Europe Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.157: Europe Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.158: Rest of World Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.159: Rest of World Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.160: Other Revenue of Bristol-Myers Squibb Company FY 2013-FY 2018 (in USD billion)
  • Exhibit 8.161: Other Revenue Growth of Bristol-Myers Squibb Company FY 2014-FY 2018 (in %)
  • Exhibit 8.162: Brand-Wise Pharmaceuticals Revenue of Bristol-Myers Squibb Company FY 2018 (in USD billion)
  • Exhibit 8.163: SWOT Analysis of Bristol-Myers Squib Company
  • Exhibit 9.1: Competitive Landscape Among Top 10 Oncology Companies by Oncology Revenue for FY2018 (in USD billion)
  • Exhibit 9.2: Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue for FY2018 (in USD billion)
  • Exhibit 9.3: Competitive Landscape Among Top 10 Oncology Companies by Global Pharmaceuticals Revenue for FY2018 (in USD billion)
  • Exhibit 9.4: Competitive Landscape Among Top 10 Oncology Companies by United States Revenue for FY2018 (in USD billion)
  • Exhibit 9.5: Competitive Landscape Among Top 10 Oncology Companies by Research and Development (R&D) Expenditure for FY2018 (in USD billion)
  • Exhibit 9.6: Competitive Landscape Among Top 10 Oncology Companies by Research and Earning Per Share (EPS) and EBITDA for FY2018 (in USD)
  • Exhibit 9.7: Competitive Landscape Among Top 10 Oncology Companies by Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for FY2018 (in USD billion)
  • Exhibit 9.8: Competitive Landscape Among Top 10 Oncology Companies by Overall Revenue Forecast for FY2019 (in USD billion)
  • Exhibit 9.9: Competitive Landscape Among Top 10 Oncology Companies by 3 Blockbuster Product Revenue for FY2018 (in USD billion)
  • Exhibit 10.1: Porter's Five Forces Analysis for Global Oncology Market
  • Exhibit 10.2: SWOT Analysis for Global Oncology Market
Back to Top